The top contributor to familial Parkinson’s disease is mutations in leucine-rich repeat kinase 2 (LRRK2), whose large and difficult structure has finally been solved, paving the way for targeted therapies.
Researchers at Washington University School of Medicine in St. Louis have discovered that the genetic variant APOE4 – long linked to dementia – spurs the spread of harmful clumps of Parkinson’s proteins through the brain. The findings suggest that therapies that target APOE might reduce the risk of dementia for people with Parkinson’s disease.
Scientists have found a way to distinguish between two progressive neurodegenerative diseases, Parkinson’s disease (PD) and multiple system atrophy (MSA), using a technology developed by a researcher at UTHealth. The discovery was published today in Nature.
Time spent playing video games is often seen as time stolen from physical activities. Research has shown that exercise has many physical and cognitive benefits.
A collaboration between scientists at Rutgers University and The Scripps Research Institute led to the discovery of a small molecule that may slow down or stop the progression of Parkinson's Disease.
People who develop Parkinson's disease before age 50 may have been born with disordered brain cells that went undetected for decades, according to EMBARGOED Cedars-Sinai research that will publish Jan. 27 in the journal Nature Medicine. The research points to a drug that potentially might help correct these disease processes.
In an article published recently in Microgravity, a Nature Journal, researchers at Rensselaer Polytechnic Institute demonstrate a unique method for studying the mechanisms behind the formation of amyloid fibrils associated with diseases like Alzheimer’s and Parkinson’s.
GB Sciences, Inc. (OTCQB: GBLX) announced significant preclinical results for their Parkinson's disease ("PD") formulations from the midterm report for their preclinical study being performed by Dr. Lee Ellis of the National Research Council (NRC) in Halifax, Nova Scotia, CANADA.
A clinical trial investigating the repurposed cancer drug nilotinib in people with Parkinson’s disease finds that it is reasonably safe and well tolerated. Researchers also report finding an increase in dopamine, the chemical lost as a result of neuronal destruction, and a decrease in neurotoxic proteins in the brain among study participants. Finally, they say nilotinib, a tyrosine kinase inhibitor, potentially halts motor and non-motor decline.
Researchers at Washington University School of Medicine in St. Louis have mapped nine functional networks in the deep-brain structures of 10 healthy people, an accomplishment that could lead to improvements in deep-brain stimulation therapy for severe cases of Parkinson’s disease and other neurological conditions.
An article published in Proceedings of the National Academy of Sciences (PNAS) describes a new pathway in the central nervous system to expel waste substances from the brain through the creation of corpora amylacea (CA), aggregates formed by glucose polymers amassing waste products.
Researchers have identified nine cases of people who lost their ability to swim after having a deep brain stimulation device implanted to control symptoms of Parkinson’s disease. The new research is published in the November 27, 2019, online issue of Neurology®, the medical journal of the American Academy of Neurology. All nine people had been good swimmers even after their Parkinson’s disease diagnosis. But once they had deep brain stimulation surgery, researchers found while other movement symptoms improved, their swimming skills deteriorated.
While most of us are enjoying the traditional turkey and pumpkin pie on Thanksgiving Day, employees at Cedars-Sinai will be hand-feeding stem cells their special daily formula, carefully monitoring the incubator temperatures and caring for the cells that may become part of important research that could one day lead to treatments for diseases that have plagued humans for years.
The five-year award will support the NINDS Human Genetics Resource Center, a collection of biological samples and corresponding demographic, clinical, and genetic data made available to qualified researchers around the world. This repository includes samples from subjects with various diseases – such as cerebrovascular disease, dystonia, epilepsy, motor neuron disease, parkinsonism, and Tourette Syndrome.
New Approach Will Lead to a Better Understanding of Most Cases
A new test agent can easily and efficiently detect the misfolded protein aggregates that cause devastating neurological diseases in blood samples. The technology could lead to early diagnosis of prion, Alzheimer's, and Parkinson's diseases for the first time.
The human brain can recognise a familiar song within 100 to 300 milliseconds, highlighting the deep hold favourite tunes have on our memory, a UCL study finds.
Physical exams only provide a snapshot of a Parkinson’s patient’s daily tremor experience. Scientists have developed algorithms that, combined with wearable sensors, can continuously monitor patients and estimate total Parkinsonian tremor as they perform a variety of free body movements in their natural settings. This new method holds great potential for providing a full spectrum of patients’ tremors and medication response, providing clinicians with key information to effectively manage and treat their patients with this disorder.
Henry Ford Health System and Montfort (Mon4t), an Israeli startup specializing in neurological disorders, have launched a pilot study related to artificial intelligence (AI) and Parkinson’s disease. In 2018, Mon4t was the winner of Henry Ford Innovations’ first AI challenge. The multi-disciplinary team responsible for leveraging Henry Ford Health System’s intellectual property, Henry Ford Innovations’ AI challenge was part of its Global Technology Development Program in Israel.
Neuroscientists at Georgetown University Medical Center say they have developed and tested an agent that reduces the buildup of toxic proteins in animal models of both Parkinson’s and Alzheimer’s diseases, and improves cognitive and motor behavior.
Human-made toxic chemicals that linger indefinitely in the environment disrupt the performance of critical helper cells in the mouse brain, leading to impaired function over long-term exposures.
A new Stony Brook University-led study, to be published in PNAS, provides a biophysical model that reveals how damage accumulates in proteins with age and is a trigger to death. The finding opens a door to a better understanding of the molecular origins of age-related neurodegenerative diseases.
A special type of PET scan used for imaging the brains of patients with Parkinson’s could be revolutionary for drug development and treatment.
Georgetown University Medical Center, a Lewy Body Dementia (LBD) Association Research Center of Excellence, is now offering three clinical trials to study new treatments for LBD, a disease often confused with Parkinson’s and Alzheimer’s disease.
An expert team from Case Western Reserve University School of Medicine has received a five-year, $3.6 million grant from the National Institutes of Health for diagnosing Parkinson's disease via an innovative skin testing approach.
Researchers from the Institute of Neurosciences of the University of Barcelona (UBNeuro), Hospital Clínic and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) have identified a group of genetic variants related to the starting point of Parkinson's disease.
David H. Zald has been appointed as the director of the new Rutgers Center for Advanced Human Brain Imaging Research at the Rutgers Brain Health Institute.
The Division of Movement Disorders at Hackensack University Medical Center has been selected to participate in the RESTORE-1 Phase 2 Clinical Study of VY-AADC, an investigational gene therapy for Parkinson’s disease.
Dr. Jeffrey Cummings, a world-renowned Alzheimer's researcher and leader in clinical trials, has been named the recipient of the 2019 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery. The prize, awarded by the Alzheimer's Drug Discovery Foundation (ADDF), recognizes leading researchers developing treatments for Alzheimer's disease and related dementias.
A team of scientists will use E. coli cells to help understand how human cells break down excess or unusable proteins into amino acids they can use.
Virginia M.Y. Lee, PhD, the John H. Ware 3rd Professor in Alzheimer’s Research in the Department of Pathology and Laboratory Medicine and director of the Center for Neurodegenerative Disease Research at the University of Pennsylvania, will receive the Breakthrough Prize in Life Sciences.
The Congress of Neurological Surgeons leads, promotes, and supports the creation and methodological processes to produce evidence-based guidelines—critical tools to confront a rapidly changing health care environment.
It might seem that there’s no downside to successful epilepsy surgery. Who wouldn’t want to be free of seizures that limit their life? But there are challenges to seizure freedom after years of living with epilepsy. The “burden of normality” can disrupt a person’s life and their relationships.
Mental singing – "singing" a rhythmic song in your head – can improve measures of walking ability not only in people with Parkinson disease (PD), but also in healthy older adults, reports a study in The Journal of Neurologic Physical Therapy (JNPT). The journal is published in the Lippincott portfolio by Wolters Kluwer.
In a new study of seven people with Parkinson’s disease, Johns Hopkins Medicine researchers report evidence that deep brain stimulation using electrical impulses jumpstarts the nerve cells that produce the chemical messenger dopamine to reduce tremors and muscle rigidity that are the hallmark of Parkinson’s disease, and increases feelings of well-being.
The discovery supports GM1 ganglioside as a potential target for Parkinson's therapy.
A de novo gene mutation that encodes a brain protein in a child with autism has been placed into the brains of mice. These mice then showed severe alterations of specific behaviors that closely resemble those seen in human autism spectrum disorder, or ASD.
As cells age, their ability to shed harmful refuse declines. New research findings suggest that the deterioration of autophagy in aged neurons—cells that never replicate and are as old as the bodies they inhabit—could be a risk factor for a suite of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), Alzheimer’s, and Parkinson’s.
Results suggest some forms of PD are an autoimmune disease triggered years before noticeable symptoms
The naturally occurring molecule N-acetylcysteine (NAC) shows benefit in a clinical trial for Parkinson’s Disease
The males of one species of butterfly are more attracted to females that are active, not necessarily what they look like, according to a recent research conducted at Augustana University.The paper, “Behaviour before beauty: Signal weighting during mate selection in the butterfly Papilio polytes,” found that males of the species noticed the activity levels of potential female mates, not their markings.
Since being diagnosed with Parkinson’s disease (PD) six years ago at the age of 29, Ben Stecher has learned a lot about not just PD, but medical science in general. He has become a patient advocate in a field where the complexity of the science often shuts out anyone who doesn’t have a PhD.
In experiments in mice, Johns Hopkins Medicine researchers say they have found additional evidence that Parkinson’s disease originates among cells in the gut and travels up the body’s neurons to the brain. The study, described in the June issue of the journal Neuron, offers a new, more accurate model in which to test treatments that could prevent or halt Parkinson’s disease progression.
For the first time, researchers in the University of Georgia's Regenerative Bioscience Center have used an imaging method normally reserved for humans to analyze brain activity in live agricultural swine models, and they have discovered that pig brains are even better platforms than previously thought for the study of human neurological conditions such as Alzheimer’s and Parkinson’s.
An international research team led by scientists at UAB has identified a fibril form of alpha-synuclein as a potential target for therapeutics that might help slow the progression of Parkinson’s disease.
L’Institut et hôpital neurologiques de Montréal (le Neuro) dirigera un partenariat en science ouverte en vue de la mise au point de médicaments de précision indiqués dans la sclérose latérale amyotrophique (SLA) et la maladie de Parkinson (MP).
The Neuro (Montreal Neurological Institute and Hospital) will lead an open science partnership to develop precision drugs for amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
Papers on dieldrin and disrupted DNA methylome, novel ach’ase reactivators, developmental neurotoxicity screening, and sex effects in ozone-mediated airway dysfunction are featured in latest issue of Toxicological Sciences.
Scientists can't make a living copy of your brain outside your body. That's the stuff of science fiction. But in a new study, they recreated a critical brain component, the blood-brain barrier, that functioned as it would in the individual who provided the cells to make it.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right